Skip to main content
SpringerLink
Log in

Cardiovascular Safety of Phosphodiesterase-5 Inhibitors

  • Chapter
Heart Disease and Erectile Dysfunction

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Oral phosphodiesterase-5 (PDE5) inhibitors have been shown to be effective oral agents for the treatment of organic, psychogenic, and mixed erectile dysfunction (ED). There are numerous PDE isoforms throughout the body (1). PDE5 is concentrated in genitalia but is also found in systemic arteries and veins throughout the body as well as in smooth muscle cells in the gastrointestinal tract and platelets (2–4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725–748.

    PubMed  CAS  Google Scholar 

  2. Poison JB, Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1996; 36: 403–427.

    Article  Google Scholar 

  3. Jackson G, Benjamen N, Jackson N, et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C - 20C.

    Article  PubMed  CAS  Google Scholar 

  4. Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C - 12C.

    Article  PubMed  CAS  Google Scholar 

  5. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802–1813.

    Article  PubMed  CAS  Google Scholar 

  6. Lincoln TM. Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther 1989; 41: 479–502.

    Article  PubMed  CAS  Google Scholar 

  7. Sâenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 2000; 12 (Suppl 4): S34 - S38.

    Article  PubMed  Google Scholar 

  8. Ückert S, Kuthe A, Stief CG, et al. Phosphodiesterase isoenzyme as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 2001; 19: 14–22.

    Article  PubMed  Google Scholar 

  9. Montorsi F, McDermott TED, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999; 53: 1011–1018.

    Article  PubMed  CAS  Google Scholar 

  10. Brock GE, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332–1336.

    Article  PubMed  CAS  Google Scholar 

  11. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral selective phosphodiesterase type 5 inhibitor, in patents with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192–199.

    Article  PubMed  CAS  Google Scholar 

  12. Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in ED patients: a Rigi Scan and pharmacokinetic study. World J Urol 2001; 19: 32–38.

    Article  PubMed  CAS  Google Scholar 

  13. Speakman MT, Kloner RA. Viagrae“ and cardiovascular disease. J Cardiovasc Pharmacol Ther 1999; 4: 259–267.

    Article  PubMed  CAS  Google Scholar 

  14. Kloner RA. Effect of sildenafil in patients with ED taking antihypertensive medications. Am J Hypertens 2001; 14: 70–73.

    Article  PubMed  CAS  Google Scholar 

  15. Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (Viagra’“) in the treatment of ED. Int J Impot Res 1998; 10: 69–74.

    Article  PubMed  CAS  Google Scholar 

  16. Zusman RM, Morales A, Glasser DB, et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83: 350–44C.

    Google Scholar 

  17. Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of ED in patients with ischemic heart disease. Am J Cardiol 1999; 83 (Suppl 5A): 29C - 34C.

    Article  PubMed  CAS  Google Scholar 

  18. Hermann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622–1626.

    Article  Google Scholar 

  19. Fox KM, Thadani U, Ma PTS, et al. Time to onset of limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: effect of sildenafil citrate. Abstract presented at American Heart Association Scientific Sessions. Circulation 2001;104(17 Suppl II):IL601–II602.

    Google Scholar 

  20. Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287: 719–725.

    Article  PubMed  CAS  Google Scholar 

  21. Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 2000; 18: 1865–1869.

    Article  PubMed  CAS  Google Scholar 

  22. Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressurelowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83: 21C - 28C.

    Article  PubMed  CAS  Google Scholar 

  23. Cheitlin MD, Hutter AM Jr., Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33: 273–282.

    Article  PubMed  CAS  Google Scholar 

  24. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002; 89: 1331–1334.

    Article  PubMed  CAS  Google Scholar 

  25. Mittleman MA, Glasser DB, Orazem J, et al. Incidence of myocardial infarction and death in 53 trials of Viagra“’ (Sildenafil citrate). J Am Coll Cardiol 2000; 35 (Suppl A): 302A.

    Google Scholar 

  26. Shakir SAW, Wilton LV, Boshier A, et al.Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 2001; 322: 651–652.

    Article  PubMed  CAS  Google Scholar 

  27. Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000;86(Suppl): 57F–61F.

    Article  PubMed  CAS  Google Scholar 

  28. Kloner RA. Sex and the patient with cardiovascular risk factors: focus on sildenafil. Am J Med 2000; 109 (Suppl 9A): 13S - 21S.

    Article  PubMed  Google Scholar 

  29. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83: 576–582.

    Article  PubMed  CAS  Google Scholar 

  30. Padma-Nathan H, Eardley I, Kloner RA, et al. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002; 60: (Suppl 2B): 67–90.

    Article  PubMed  Google Scholar 

  31. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36: 25–31.

    Article  PubMed  CAS  Google Scholar 

  32. Przyklenk K, Kloner RA. Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. J Am Coll Cardiol 2001; 37: 286–292.

    Article  PubMed  CAS  Google Scholar 

  33. Reffelmann T, Kloner RA. Effect of sildenafil on myocardial infarct size, microvascular function, and acute ischemic ventricular dilation. Cardiovasc Res 2003; 59: 441–449.

    Article  PubMed  CAS  Google Scholar 

  34. Padma-Nathan H, McMurray JG, Pullman WE, et al., for the tadalafil On-Demand Dosing Study Group. On-demand tadalafil (Cialis’’) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13: 2–9.

    Article  PubMed  CAS  Google Scholar 

  35. Kloner RA, Watkins VS, Costigan TM, et al. Cardiovascular profile of tadalafil, a new PDE5 inhibitor. J Urol 2002; 167 (Suppl 4): 176.

    Google Scholar 

  36. Kloner RA, Emmick J, Bedding A, et al. Pharmacodynamic interactions between tadalafil and nitrates [abstract]. J Am Coll Cardiol 2002; 39 (Suppl A): 291A.

    Article  Google Scholar 

  37. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J 2002; 4: (Suppl H): H32 - H47.

    CAS  Google Scholar 

  38. Kloner RA, Mitchell M, Bedding A, et al. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J Urol 2002; 167 (Suppl): 176–177.

    Google Scholar 

  39. Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42: 1855–1860.

    Article  PubMed  CAS  Google Scholar 

  40. Patterson D, MacDonald TM, Effron MB, et al. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Circulation 2002;(Suppl 1I)106:1I-330.

    Article  Google Scholar 

  41. Kloner RA, Mitchell M, Emmick IT. Cardiovascular effects of tadalafil in patients on commonly used classes of antihypertensive therapy. Am J Cardiol 2003; 92 (Suppl): 47M - 57M.

    Article  PubMed  CAS  Google Scholar 

  42. Mazzu A, Nicholls A, Zinny M. Vardenafil, a new selective PDE-5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged male subjects. Int J Impot Res 2001; 13 (Suppl 5): S64.

    Google Scholar 

  43. Kloner RA, Mohan P. Segerson T, et al. Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of five placebo-controlled clinical trials. J Am Coll Cardiol 2003; 41 (Suppl A): 276A - 277A.

    Article  Google Scholar 

  44. Kloner RA, Mohan P, Norenberg C, et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE5 inhibitor in patients with erectile dysfunction: an analysis of five-controlled clinical trials. Pharmacol Ther 2002; 22: 1371.

    Google Scholar 

  45. Padma-Nathan H, Porst H, Eardley I, et al. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on anti- ’ hypertensive therapy. Presented at the American Society of Hypertension 17th Annual Scientific Meeting. New York, NY, 2002.

    Google Scholar 

  46. Thadani U, Smith U, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase 5-inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 2006–2012.

    Article  PubMed  CAS  Google Scholar 

  47. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendation of the Princeton Consensus Panel. Am J Cardiol 2000; 86: 175–181.

    Article  PubMed  CAS  Google Scholar 

  48. Zhao L, Mason NA, Morrell N, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: 424–428.

    Article  PubMed  CAS  Google Scholar 

  49. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343: 1342.

    Article  PubMed  CAS  Google Scholar 

  50. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218–1222.

    Article  PubMed  CAS  Google Scholar 

  51. Katz SD, Balideinaj K, Homma S, et al. Acute type 5 phosphodiesterase inhibitor with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845–851.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Robert A. Kloner MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Robert A. Kloner MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Kloner, R.A. (2004). Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. In: Kloner, R.A. (eds) Heart Disease and Erectile Dysfunction. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-748-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-748-2_9

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9849-3

  • Online ISBN: 978-1-59259-748-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation